You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 6, June 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Quality of Life
 •Neoplasms
 •Alert me on articles by topic

The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma

Therapeutic Breakthroughs Remain Elusive

Matthew H. Kanzler, MD

Arch Dermatol. 2007;143(6):785-787.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this month's ARCHIVES, González1 and Tsai2 provide evidence-based critiques of 2 recently published articles regarding cutaneous melanoma. These articles evaluate the clinical utility of sentinel node biopsies (SNBs) and systemic therapy for patients with high-risk melanoma. Both topics have generated much discourse over the past decade, as until recently, "standards of care" have been dictated by theories and consensus owing to the lack of good evidence.

González1 provides an excellent commentary on the results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I),3 which evaluated the effectiveness of SNB in patients with cutaneous melanoma. The MSLT-I is an excellent example of a "negative" study given a positive "spin" by the authors. In fact, the negative results of the primary aim of this study are nowhere to be found in the conclusions of the article's abstract.

While the MSLT-I was generally well designed and executed, inappropriate use . . . [Full Text of this Article]


AUTHOR INFORMATION

RELATED ARTICLES

Cloud Over Sentinel Node Biopsy: Unlikely Survival Benefit in Melanoma
Urbà González
Arch Dermatol. 2007;143(6):775-776.
EXTRACT | FULL TEXT  

Systemic Adjuvant Therapy for Patients With High-Risk Melanoma
Kenneth Y. Tsai
Arch Dermatol. 2007;143(6):779-782.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sentinel Node Biopsy: Facts to Clear the Alleged Clouds--Reply
Gonzalez
Arch Dermatol 2008;144:687-687.
FULL TEXT  

Lymphatic Mapping and Sentinel Node Biopsy: The Data Unclouded by Speculation--Reply
Kanzler
Arch Dermatol 2008;144:688-689.
FULL TEXT  

Lymphatic Mapping and Sentinel Node Biopsy: The Data Unclouded by Speculation
Cochran and Thompson
Arch Dermatol 2008;144:687-688.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.